European Medical Solutions (ALEMS.BR)
EUR 5.4
(-1.82%)
EUR 5.4
(-1.82%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 33.86 Million EUR | 15.77% |
| 2022 | 29.25 Million EUR | 15.15% |
| 2021 | 25.4 Million EUR | 135.83% |
| 2020 | 10.77 Million EUR | -1.9% |
| 2019 | 10.98 Million EUR | 115.93% |
| 2018 | 5.08 Million EUR | 64.81% |
| 2017 | 3.08 Million EUR | 27.36% |
| 2016 | 2.42 Million EUR | -61.73% |
| 2015 | 6.33 Million EUR | 395.07% |
| 2014 | 1.27 Million EUR | -3.62% |
| 2013 | 1.32 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 31.17 Million EUR | 6.55% |
| 2023 Q4 | 33.86 Million EUR | 8.65% |
| 2023 FY | 33.86 Million EUR | 15.77% |
| 2022 Q4 | 29.25 Million EUR | 5.64% |
| 2022 Q2 | 27.69 Million EUR | 469.56% |
| 2021 Q2 | 10.44 Million EUR | -3.03% |
| 2021 Q4 | 4.86 Million EUR | -53.46% |
| 2020 Q4 | 10.77 Million EUR | -2.94% |
| 2020 Q2 | 11.09 Million EUR | 1.07% |
| 2019 Q2 | 4.32 Million EUR | -14.92% |
| 2019 Q4 | 10.98 Million EUR | 153.8% |
| 2018 Q2 | 4.64 Million EUR | 50.42% |
| 2018 Q4 | 5.08 Million EUR | 9.56% |
| 2017 Q4 | 3.08 Million EUR | -26.14% |
| 2017 Q2 | 4.17 Million EUR | 72.43% |
| 2016 Q2 | 2.86 Million EUR | -54.79% |
| 2016 Q4 | 2.42 Million EUR | -15.37% |
| 2015 Q4 | 6.33 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nicox S.A. | 31.56 Million EUR | -7.283% |
| FERMENTALG | 19.39 Million EUR | -74.585% |
| argenx SE | 402.79 Million EUR | 91.592% |
| BioSenic S.A. | 32.26 Million EUR | -4.965% |
| Celyad Oncology SA | 9.97 Million EUR | -239.407% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -293.242% |
| Onward Medical N.V. | 25.69 Million EUR | -31.785% |
| Oxurion NV | 19.73 Million EUR | -71.595% |
| PHAXIAM Therapeutics S.A. | 25.69 Million EUR | -31.8% |
| Financière de Tubize SA | 123.65 Million EUR | 72.611% |
| UCB SA | 6.56 Billion EUR | 99.484% |